Population-Level Impact of Emicizumab in Algeria: A 25-Year Projection
Author(s)
Wafaa Manel M. BENNOUNA, PharmD1, Khalifa Islam BENGANA, PharmD2, Latifa Lamhene, .3, Abdelhakim Boudis, Prof.1.
1University of Health Sciences, Algiers, Algeria, 2Roche Algérie SPA, Algiers, Algeria, 3Association Nationale des Hémophiles Algériens, Algiers, Algeria.
1University of Health Sciences, Algiers, Algeria, 2Roche Algérie SPA, Algiers, Algeria, 3Association Nationale des Hémophiles Algériens, Algiers, Algeria.
OBJECTIVES: The management of hemophilia A represents an estimated annual cost up to 10 Billion DZD (69 million euros) for Algeria. With innovative treatments being introduced as standards of care in prophylaxis settings, it is essential to study their potential societal impact to put their value into perspective.
METHODS: Using a statistical projection model, the clinical, economic, and societal consequences of introducing Emicizumab for the treatment of the Algerian pediatric population (0-18 years old), with severe hemophilia A, and without Factor VIII inhibitors (INH-); were evaluated over a 25-year time horizon. A comprehensive literature review documented the model's parameters.
RESULTS: Clinically, the introduction of Emicizumab reduced the total number of bleeds by 39% on average over 25 years (i.e., 6,240 avoided events, including 4,555 joint bleeds). The model also showed a decrease in the incidence of Factor VIII inhibitors, with the proportion of INH- patients reaching 78% of the cohort by the 25th year. These clinical improvements resulted in a gain of 1,276 QALYs over 25 years (an average of +49 QALYs per year) and a reduction in absenteeism (an average of -1,721 days per year). Direct medical costs decreased by 39%, in the scenario with Emicizumab versus the scenario without, generating 778 million DZD (5.1 million euros) in savings over 25 years. Indirect costs were reduced by approximatively 60 million DZD (396k euros) over the same period.
CONCLUSIONS: The adoption of Emicizumab demonstrates substantial clinical and socio-economic benefits for the Algerian population. In the long term perspective the significant reduction in bleeding rates translates into a notable improvement in quality of life and will generate substantial savings on direct and indirect costs. Moreover the potential to prevent the development of Factor VIII inhibitor reduces the high risk of complications and their associated high costs.
METHODS: Using a statistical projection model, the clinical, economic, and societal consequences of introducing Emicizumab for the treatment of the Algerian pediatric population (0-18 years old), with severe hemophilia A, and without Factor VIII inhibitors (INH-); were evaluated over a 25-year time horizon. A comprehensive literature review documented the model's parameters.
RESULTS: Clinically, the introduction of Emicizumab reduced the total number of bleeds by 39% on average over 25 years (i.e., 6,240 avoided events, including 4,555 joint bleeds). The model also showed a decrease in the incidence of Factor VIII inhibitors, with the proportion of INH- patients reaching 78% of the cohort by the 25th year. These clinical improvements resulted in a gain of 1,276 QALYs over 25 years (an average of +49 QALYs per year) and a reduction in absenteeism (an average of -1,721 days per year). Direct medical costs decreased by 39%, in the scenario with Emicizumab versus the scenario without, generating 778 million DZD (5.1 million euros) in savings over 25 years. Indirect costs were reduced by approximatively 60 million DZD (396k euros) over the same period.
CONCLUSIONS: The adoption of Emicizumab demonstrates substantial clinical and socio-economic benefits for the Algerian population. In the long term perspective the significant reduction in bleeding rates translates into a notable improvement in quality of life and will generate substantial savings on direct and indirect costs. Moreover the potential to prevent the development of Factor VIII inhibitor reduces the high risk of complications and their associated high costs.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
PCR187
Topic
Economic Evaluation, Patient-Centered Research
Disease
Pediatrics, Rare & Orphan Diseases, Systemic Disorders/Conditions (Anesthesia, Auto-Immune Disorders (n.e.c.), Hematological Disorders (non-oncologic), Pain)